What does “all-in price” mean for GLP-1 programs?
An all-in GLP-1 price is what a telehealth program charges each billing cycle once every required charge is counted, meaning the medication, any required membership or program fee and the clinician care, at the maintenance dose of 10 mg tirzepatide or 2.4 mg semaglutide and before prepaid discounts. It matters because headline prices often leave out a fee or quote a starting dose: IVIM Health’s page, read November 20, 2026, shows tirzepatide “starting at” $117 a month plus a $75 monthly program fee, at least $192 all-in. A 28-day cycle adds a 13th charge to the year.
Released · Last reviewed · how we verify
Limitations of this answer
Compounded tirzepatide and semaglutide are not FDA-approved and are not the same products as Zepbound or Wegovy. This page reports prices and terms; whether any GLP-1 suits you is a decision for you and a licensed clinician.
Frequently asked
What does “all-in price” mean for GLP-1 programs?
An all-in GLP-1 price is what a telehealth program charges each billing cycle once every required charge is counted, meaning the medication, any required membership or program fee and the clinician care, at the maintenance dose of 10 mg tirzepatide or 2.4 mg semaglutide and before prepaid discounts. It matters because headline prices often leave out a fee or quote a starting dose: IVIM Health’s page, read November 20, 2026, shows tirzepatide “starting at” $117 a month plus a $75 monthly program fee, at least $192 all-in. A 28-day cycle adds a 13th charge to the year.
How current are the prices on TopGLP1Providers?
Every price on TopGLP1Providers carries the date it was read on the program’s own page; the whole dataset was re-read on November 20, 2026, from 2026-11-21 00:33 to 00:57 UTC, and NexLife’s plan pages were checked again for this site on November 21 (UTC). Programs whose pages refused automated reads that day, such as TrimRx, MEDVi, bmiMD, Embody, Ro and Hims & Hers, show no current price rather than an older one. When a program changes its price, the record, the pages that cite it and the changelog are updated together.
Sources
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026; read November 20, 2026)
- Zepbound (tirzepatide) prescribing information on DailyMed (read November 20, 2026)
- Wegovy (semaglutide) prescribing information on DailyMed (read November 20, 2026)